Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 3/20 | 0.47 |
| ▸ | PRKCB | P05771 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.42 |
| ▸ | GRM1 | Q13255 | 4/20 | 0.41 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | SLC5A7 | Q9GZV3 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20012519 | 0.84 | IDH1 (0.45) | IDH1PRKCBPARP1HRH3GRM1 | |
| SCHEMBL18705021 | 0.81 | KDM4E (0.55) | HRH3ALDH1A1CNR1KDM4E | |
| SCHEMBL9963404 | 0.77 | LMNA (0.45) | HRH3ALDH1A1LMNAKDM4E | |
| SCHEMBL9963401 | 0.77 | LMNA (0.45) | HRH3ALDH1A1LMNAKDM4E | |
| SCHEMBL26243687 | 0.77 | PRKCB (0.42) | PRKCBHRH3GRM1LMNA | |
| SCHEMBL24711724 | 0.72 | SMN1; SMN2 (0.44) | IDH1HRH3CYP2D6 | |
| SCHEMBL9963407 | 0.72 | LMNA (0.45) | HRH3ALDH1A1LMNASIGMAR1 | |
| SCHEMBL20008967 | 0.72 | SMO (0.50) | — | |
| SCHEMBL26123795 | 0.72 | L3MBTL1 (0.50) | IDH1PARP1HRH3GRM1ALDH1A1 | |
| SCHEMBL27883939 | 0.71 | IDH1 (0.48) | IDH1PARP1GRM1LIMK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | SMARCC1, SMARCC2, SMARCA4 | IDH1 2456/4885PRKCB 1196/4885PARP1 671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.